Evidence map›Paper›PMID 26408684›Full record

ArticleAnticancer research2015

The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression.

Chloe Stengel, Simon P Newman, Mathew P Leese, Mark P Thomas, Barry V L Potter, Michael J Reed, Atul Purohit, Paul A Foster

Open access · greenAbstract read
In one paragraph

Article in Anticancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. 2-Methoxyestradiol-3,17-International journal of molecular sciences · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chloe StengelOncology Drug Discovery and Women's Health Group, Faculty of Medicine, Imperial College London, St Mary's Hospital, London, U.K.
Simon P NewmanOncology Drug Discovery and Women's Health Group, Faculty of Medicine, Imperial College London, St Mary's Hospital, London, U.K.
Mathew P LeeseMedicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, U.K.
Mark P ThomasMedicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, U.K.
Barry V L PotterDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford, U.K. Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, U.K.
Michael J ReedOncology Drug Discovery and Women's Health Group, Faculty of Medicine, Imperial College London, St Mary's Hospital, London, U.K.
Atul PurohitOncology Drug Discovery and Women's Health Group, Faculty of Medicine, Imperial College London, St Mary's Hospital, London, U.K.
Paul A FosterOncology Drug Discovery and Women's Health Group, Faculty of Medicine, Imperial College London, St Mary's Hospital, London, U.K. Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, U.K. p.a.foster@bham.ac.uk.
St Mary's Hospital · GBUniversity of Bath · GBBirmingham Women's Hospital · GB

Funding

Wellcome Trust 101010
6 · The paper itself

Abstract

Tumor neo-angiogenesis is regulated, in part, by the hypoxia-inducible gene HIF1. Evidence suggests HIF1 associates with polymerized microtubules and traffics to the nucleus. This study investigated the role of HIF1 in mediating the antitumor activity of two steroid-based sulfamate ester microtubule disruptors, STX140 and STX243, in vitro and in vivo. The effects of STX140, STX243 and the parental compound 2-methoxyestradiol (STX66) on HIF1α and HIF2α protein expression were assessed in vitro in MCF-7 and MDA-MB-231 cells cultured under hypoxia. More pertinently, their effects were examined on HIF1-regulated genes in vivo in mice bearing MCF-7 or MDA-MB-231 tumors. The level of mRNA expression of vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUTI), phosphoglycerate kinase (PGK), ATP-binding cassette sub-family B member 1 (ABCB1) and carbonic anhydrase IX (CAIX) was quantified by Real-time Polymerase Chain Reaction (RT-PCR). Despite inhibiting nuclear HIF1α protein accumulation under hypoxia in vitro, STX140 and STX243 did not significantly regulate the expression of four out of five HIF1α-regulated genes in vitro and in vivo. Only CAIX mRNA expression was down-regulated both in vitro and in vivo. Immunoblot analysis showed that STX140 and STX243 reduced CAIX protein expression in vitro. These compounds had no effect on HIF2α translocation. The potential for inhibition of CAIX by STX140 and STX243 was examined by docking the ligands to the active site in comparison with a known sulfamate-based inhibitor. Microtubule disruption and antitumor activity of STX140 and STX243 is most likely HIF1-independent and may, at least in part, be mediated by inhibition of CAIX expression and activity.

Indexed as

AnimalsAntigens, NeoplasmCarbonic Anhydrase IXCarbonic AnhydrasesCell HypoxiaCell Line, TumorEstradiolEstrenesFemaleGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitMammary Neoplasms, ExperimentalMCF-7 CellsMiceMolecular Docking Simulation2-ethyloestradiol-bis-sulfamate2-methoxyestradiol-3,17-O,O-bis(sulfamate)Antigens, NeoplasmCA9 protein, humanCarbonic Anhydrase IXCarbonic AnhydrasesEstradiolEstrenesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitSulfonic AcidsTubulin Modulatorsanti-angiogenicCAIXHIF1AMCF-7 cellsMDA-MB-231 cellsmicrotubule disruptorVEGFxenografts

Identifiers

PMID26408684
PMCPMC4597367
OpenAlexW2131649392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.